Loading stock…

SCHOTT Pharma AG & Co. KGaA (1SXP) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

SCHOTT Pharma AG & Co. KGaA

1SXPMarket cap $4.25BPrice $28.2

Country🇩🇪Germany

SectorHealthcare

IndustryLife Sciences

Manufactures glass and polymer containment solutions—vials, syringes, cartridges—that protect and deliver injectable drugs and vaccines worldwide. Nearly every major pharma company relies on their pharmaceutical packaging, making them a quiet but essential link in the global vaccine and biologics supply chain.

In Bastion Portfolios?

52W Return+23%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+13%8

Revenue Forecast

Rev CAGR (1y)+2%3

Rev CAGR (3y)+6%5

Rev CAGR (5y)+6%5

Earnings Forecast

EPS Growth Y+1-2%3

EPS Growth Y+2+11%7

EPS Growth Y+3+10%7

Quality

Margins

EBIT Margin16%6

Net Income Margin13%7

Free Cash Flow Margin5%4

Debt

Net Debt/EBITDA1.16

Efficiency

ROE15%6

ROA8%8

Earnings Stability88

GEAR+AVERAGE49

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)214

P/E Ratio (Forward 3y)213

P/BV3.84

EV Multiples

EV/EBITDA Fwd144

EV/EBIT Fwd204

Yield

Free Cash Flow Yield1.5%4

Dividend Yield0.7%2

Momentum

Short term

1 month return+8%10

3 month return+35%10

YTD return+67%10

Mid term

Price vs 52wHigh96%10

1 year return+21%7

Long term

3 year return-19%2

5 year return-19%3

Risk Shield

Price Risk

Beta1.04

Volatility33%6

Free Cash Flow

Free Cash Flow Margin5%4

Free Cash Flow Yield1.5%4

Quality

ROCE14%7

Earnings Stability88

Net Debt/EBITDA1.16

02Growth

Is it actually growing, and how fast?

1SXPSCHOTT Pharma AG & Co. KGaA

Revenue FY25$1.2B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+13%8

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+6%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-2%3

EPS growth, FY27E+11%7

EPS growth, FY28E+10%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 13%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 13%/yr over the last 3 years; forecasts see it cooling to 6%/yr.

Over five years revenue is set to grow 6%/yr, about average versus companies worldwide.5/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 6%/yr). One year dips: EPS falls 2% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

1SXPSCHOTT Pharma AG & Co. KGaA

Total return Current−15.4%

Price return Current−16.5%

MOMENTUM RATING↗

STRONG77 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+8%10

3-month return+35%10

YTD return+67%10

MID & LONG-TERM▾SCORE

% of 52-week high96%10

1-year return+21%7

3-year return-19%2

5-year return-19%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 21% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+8%), over three months (+35%) and so far this year (+67%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-19% over three years and -19% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on SCHOTT Pharma AG & Co. KGaA. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

1SXPSCHOTT Pharma AG & Co. KGaA

Revenue FY25$1.2B

GROWTH RATING↗

AVERAGE45 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+13%8

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+6%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-2%3

EPS growth, FY27E+11%7

EPS growth, FY28E+10%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 13%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

WATCH

A mid-pack grower, ahead of 45% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 13%/yr over the last 3 years; forecasts see it cooling to 6%/yr.

Over five years revenue is set to grow 6%/yr, about average versus companies worldwide.5/10

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 6%/yr). One year dips: EPS falls 2% next year.

WEAKNESSES

None flagged.

BOTTOM LINE

Maturing Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

1SXPSCHOTT Pharma AG & Co. KGaA

Total return Current−15.4%

Price return Current−16.5%

MOMENTUM RATING↗

STRONG77 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+8%10

3-month return+35%10

YTD return+67%10

MID & LONG-TERM▾SCORE

% of 52-week high96%10

1-year return+21%7

3-year return-19%2

5-year return-19%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 21% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+8%), over three months (+35%) and so far this year (+67%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-19% over three years and -19% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on SCHOTT Pharma AG & Co. KGaA. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community